Chinese biotech developing monoclonal antibodies and antibody-drug conjugates (ADCs) for cancer and other diseases.
Chinese biotech developing monoclonal antibodies and antibody-drug conjugates (ADCs) for cancer and other diseases.
In one line: A Chinese ADC-focused biotech, akin to a smaller Seagen.
Moat: narrow (IP / patents). Patent-protected antibody/ADC pipeline built on in-house biologics R&D.
Headquarters: Shanghai, China · Employees: 1,325
Size Mabwell (Shanghai) Bioscience (688062.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.20B, the 1849th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥18.50 on 18 Nov 2026.
Performance Over six months the shares fell 46.1%, against -17.3% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue grew 14.9% over the last twelve months (peer median +3.1%); the operating margin is -128.8% (peer median 0.8%).
Valuation It trades at 13.3× enterprise value to sales against a peer median of 7.6× (5th most expensive of 18).
Capital Return on invested capital runs 32.5 points below its cost of capital (9.1% WACC).
Next results Next results expected around 7 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥718M | CN¥661M | CN¥198M | CN¥127M | CN¥27.7M |
| Revenue growth | — | +233% | +57% | +357% | — |
| Gross profit | CN¥594M | CN¥387M | CN¥39.6M | CN¥15.8M | -CN¥68.2M |
| EBITDA | n/a | -CN¥672M | -CN¥885M | -CN¥979M | -CN¥907M |
| Net income | -CN¥1.05B | -CN¥969M | -CN¥1.04B | -CN¥1.05B | -CN¥955M |
| Free cash flow | -CN¥1.04B | -CN¥447M | -CN¥1.28B | -CN¥1.28B | -CN¥1.26B |
| Capital expenditure | CN¥107M | CN¥158M | CN¥330M | CN¥500M | CN¥545M |
| Total debt | CN¥3.69B | CN¥2.97B | CN¥2.22B | CN¥1.29B | CN¥774M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience 688062.SS | $1.20B | -46% | +15% | -129% | 13.3× | n/a |
| RemeGen 688331.SS | $6.28B | -24% | +272% | 61% | 4.4× | 1.1% |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 7.3× | 11.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688062.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -18.9% | -5.1% | 2nd lowest of 21 |
| 6-month return | -46.1% | -17.3% | 4th lowest of 21 |
| Distance from 52-week high | -61.3% | -39.3% | 5th lowest of 21 |
| Revenue growth (TTM) | +14.9% | +3.1% | 7th highest of 18 |
| Operating margin | -128.8% | 0.8% | 4th lowest of 18 |
| EV / Sales | 13.3× | 7.6× | 5th most expensive of 18 |
| ROIC minus cost of capital | -32.5 pp | -5.1 pp | 5th lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.20B | -46% | +15% | -129% | 13.3× | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.21B | +26% | -6% | -19% | 10.4× | 44.1% | -13.2% |
| CStone Pharmaceuticals 2616.HK | Hong Kong | $1.21B | -22% | +117% | -89% | 17.0× | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 4.7× | n/a | n/a |
| Shenzhen Chipscreen Biosciences 688321.SS | China | $1.18B | -38% | +27% | 12% | 7.6× | n/a | n/a |
| Chongqing Genrix Biopharmaceutical 688443.SS | China | $1.18B | -22% | +256% | -27% | 8.6× | n/a | n/a |
| Nektar Therapeutics NKTR | United States | $1.18B | -50% | -17% | -304% | 13.3× | n/a | n/a |
| Ascentage Pharma Group International 6855.HK | Hong Kong | $1.18B | -34% | +70% | -220% | 13.2× | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | 818.8× | n/a | n/a |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | 10.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 1.8× | 7.0% | -5.3% |
| Jiuzhitang 000989.SZ | China | $1.16B | -7% | +46% | 19% | 2.6× | -4.0% | -9.0% |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 0.5× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 4.8× | 3.4% | +27.9% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Kissei Pharmaceutical 4547.T | Japan | $1.14B | +3% | +6% | 6% | 1.4× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 39.1× | n/a | n/a |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.14B | -12% | -2% | 15% | 4.2× | 3.4% | -1.2% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 2.3× | 2.5% | +15.5% |